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Introduction
Although there are currently few approved pharmacological treatments to assist with long-term weight loss in overweight or obese patients, those that have targeted serotonergic signaling have a history of modest success. Two current FDA-approved drugs for weight loss, the phentermine/topiramate combination (Qsymia ® ) and lorcaserin (Belviq ® ), increase serotonin signaling. Phentermine increases serotonin (5-HT) tone in the synapse, whereas lorcaserin is a selective agonist at the 5-HT 2C receptor. Systemic stimulation of 5-HT 1B and 5-HT 2C receptors decreases food intake, causing reductions in meal size and duration that have been interpreted as advancing satiety processes [e.g. [1] [2] [3] [4] [5] ]. The recent success of lorcaserin in assisting weight loss provides hope that serotonin-based therapies that target individual serotonin subtypes may be of use in combatting obesity, without the cardiovascular side effects that resulted in the market removal of prior agents such as sibutramine and the phentermine/fenfluramine combination (phen-fen). The effects of serotonergic agents on satiety and meal size appear to be the result of their actions on the central nervous system, as injections of 5-HT 1B or 5-HT 2C agonists into the parabrachial and hypothalamic nuclei, respectively, also reduce feeding [e.g. [4, 6] ]. Recent work has begun to examine what role, if any, the various 5-HT receptors of the mesoaccumbens pathway may have on feeding and food-directed motivation. This pathway is of particular interest, as it has been argued to promote the overconsumption of palatable diets based upon their rewarding and reinforcing properties, and is differentially activated by food cues in individuals who are obese or are at risk of becoming obese [7] [8] [9] [10] [11] . Within the nucleus accumbens (NAcc) shell, stimulation of the 5-HT 1A (but not 5-HT 1B or 5-HT 7 ) receptors inhibits feeding, albeit with concomitant locomotor alterations [12, 13] . Jean et al. reported that 5-HT 4 receptors of the NAcc inhibit food intake and are responsible for the anorexia observed following systemic 3,4-Nmethylenedioxymethamphetamine (MDMA, ecstasy) treatment in mice [14] . In contrast to the reduced feeding caused by 5-HT 1A and 5-HT 4 receptor stimulation, 5-HT 6 receptor agonism of the NAcc increases food intake [13] . Additionally, stimulation of 5-HT 1A , 5-HT 1B, and 5-HT 2B receptors (but not 5-HT 2A or 5-HT 2C receptors) within the ventral tegmentum alters feeding in rats [15] . Clearly, serotonin afferents to the mesoaccumbens pathway are well-positioned to regulate motivated behavior, and serotonin's impact on food-directed motivation depends upon the particular receptor subtype engaged within these regions.
The 5-HT 3 receptor is unique amongst the serotonin receptor classes, as it is the only serotonin receptor that directly opens a cation channel, rather than acting as a g-protein coupled receptor. 5-HT 3 receptors are found peripherally and in the central nervous system, and drugs that antagonize this receptor have been useful for their anti-emetic properties [16] . With regards to the central control of food intake, it has been shown that 5-HT 3 receptors of the nucleus of the solitary tract regulate meal size and suppress feeding in response to cholecystokinin [17, 18] . 5-HT 3 receptors are also found within the ventral tegmental area (VTA) and the NAcc in rats and humans [19] [20] [21] , and it is likely that they serve important regulatory functions. Specifically, 5-HT 3 receptor stimulation in either the VTA or NAcc increases dopamine output [22, 23] , and 5-HT 3 receptor antagonists reduce mesoaccumbens dopamine signaling in response to several abuse-prone drugs, such as alcohol [for review, see Ref. [24] ], cocaine [e.g. [25, 26] ], and morphine [e.g. [25, 27] ]. Given that drugs of abuse impact the same neural pathways implicated in the reinforcing and rewarding properties of food, these experiments were conducted to test whether stimulation or blockade of 5-HT 3 receptors of the NAcc and ventral tegmentum might regulate feeding, motivated either by energy need or by the presence of a palatable sweetened fat diet.
Materials and methods

Animals and housing
Sixty-six adult male Sprague-Dawley rats (Harlan, Madison, WI; 275-300 g at arrival) were acclimated to dual housing in a colony room maintained at ∼21 • C with a 12-h light-dark cycle (lights on at 7 a.m.). All experiments were conducted in accordance to NIH animal care guidelines and were approved by the Wake Forest University Animal Care and Use Committee.
Surgical procedures
Following acclimation to the housing environment and daily handling, rats were anesthetized with a Ketamine-Xylazine cocktail (100 mg/kg-10 mg/kg). Standard aseptic surgical procedures were used to implant indwelling stainless steel guide cannulas (23 gauge) bilaterally above the NAcc shell (with the nose bar set at 5 mm above interaural zero: 3.1 mm anterior and 1.0 mm lateral to bregma, 5.0 mm ventral to the skull surface) or the VTA (with the skull flat; −5.6 mm posterior and 0.6 mm lateral to bregma, 7.3 mm ventral to skull surface). Stylets were placed within the cannulas to maintain patency. Rats were given at least one full week of recovery before acclimation to the feeding chambers and subsequent behavioral testing.
Apparatus
Food intake was monitored during 2-h feeding sessions in experimental chambers. The feeding chambers were constructed from clear acrylic, with internal dimensions 42 cm wide, 30.5 cm deep and 33 cm tall. A water bottle was hung at one end of the chamber, and a food hopper was available at the opposite end of the chamber. The hopper was filled with diet and mounted on a food intake monitor (head entry at 6.4 cm above the wire floor). Each food intake monitor consisted of a calibrated potentiometer which allowed for continuous monitoring of the mass/weight of the food hopper during the experimental sessions (Med Associates, St. Albans, VT). Infra-red eyebeams were located along the floor at three locations (5 cm above the wire floor) to measure ambulation; four additional IR beams were placed at a height of 16 cm above the floor to index rearing behavior. IR beam interruption (including at a sensor at the entry to the food intake monitor) was continually recorded by Med-PC software (Med Associates, St. Albans, VT). The weights of the food hoppers were monitored by the computer at 10-s intervals. A speaker maintained an ambient level of white noise at 65 dB in the experimental room.
Food-restriction feeding paradigm
The effects of drug infusion on hunger-driven food intake were tested in four groups of rats given free access to rat chow during a food-restricted state. Following one week of surgical recovery, rats were gradually reduced and maintained at approximately 90% of their ad libitum body weight. The animals then received six consecutive days of habituation to the feeding chambers prior to pharmacological treatments. Each session consisted of 2 h of free access to rat chow (Prolab RMH 3000, Purina Lab Diets, 3.46 Kcal/gr) and water. When required, rats were given additional chow outside of the experimental chambers to maintain their 90% weight; most rats consumed the daily ration required to maintain their weight within the 2-h testing sessions.
On the final 2 days of habituation, rats received mock infusions to allow acclimation to microinfusion procedures, as previously described [13] . Experimental treatments began 48 h after the last mock infusion. During vehicle and drug infusions, injection cannulas (30 gauge) were lowered into the NAcc (2.5 mm beyond the end of the guide cannulas) or the ventral tegmentum (1.0 mm beyond the end of the guide cannulas), and 0.5 l of solution was delivered (at a rate of 0.32 l/min) by a Harvard Apparatus microinfusion pump (Holliston, MA). Injectors remained in place for one minute after drug delivery to allow for diffusion. Injectors were removed, stylets replaced, and rats were immediately placed into the feeding chambers. Dependent measures included the amount of chow eaten across the 2-h period, ambulation within the chamber (assessed as the number of complete crossings of the chamber from end to end), number of rears recorded, and total water intake across the feeding session.
Feeding paradigm on a palatable fat/sucrose diet
Separate groups of rats were tested for the effects of NAcc or ventral tegmentum treatment with 5-HT 3 receptor agonists and antagonists on the intake of a highly palatable diet in non-deprived rats. Following one week of surgical recovery, ad libitum fed rats were given at least six days of habituation to the palatable diet for 2-h sessions in the feeding chambers. The high-fat diet contained 278.3 g/kg vitamin free casein, 100.0 g/kg sucrose, 4.2 g/kg dl-methionine, 441.2 g/kg shortening, 77.7 g/kg safflower oil, 26.3 g/kg cellulose, 53.3 g/kg mineral mix, 15.2 g/kg vitamin mix and 3.8 g/kg choline chloride (Kilocaloric value of diet = 6.2 kcal/g; Teklad Diets, Madison, WI, USA). Rats typically eat this diet when available, and we have previously shown that its intake is sensitive to intracranial injections of serotonergic, opiate or cholinergic drugs [e.g. [12, 15, [28] [29] [30] ]. On experimental days, mock injections and drug infusions were delivered as described for the food restriction paradigm above.
Drugs and experimental groups
These experiments assessed the behavioral effects of 5-HT 3 . Separate groups of animals were tested for each brain region (NAcc and ventral tegmentum), for each drug (agonist and antagonist), and for each dietary condition (foodrestricted or palatable eating), for a total of eight experimental groups. Within each experiment, rats received all doses of a single drug in a randomized order over 3-4 infusion days. Drug infusions were separated by a minimum of 48 h to allow for washout and metabolism of drug between injections. Drug concentrations for each agent were chosen based upon solubility and consistency with behaviorally-effective doses in other paradigms, when available [17, 31, 32] .
Histology
Once the experiments were complete, rats were euthanized and the brains were collected for standard histological analysis. Brain sections were taken through the extent of the NAcc or ventral tegmentum and stained with cresyl violet. Placement of the injection sites was confirmed by light microscopy and charted with reference to Paxinos and Watson [33] . Only the fifty-seven animals who completed all days of the experiment and whose injectors were bilaterally placed within the anterior medial NAcc or ventral tegmentum were included in the behavioral analysis.
Data analysis
Feeding data were analyzed utilizing two-way repeated measures ANOVAs, comparing food intake assessed across time (at 5 min intervals within each 2-h session) and drug doses. For groups that had significant drug and/or drug x time interaction effects, ANOVAs were run to compare the main effects of drug dose at 5 min time points across the session, in order to further assess consistency and time course of the drug effects. Total ambulation, rearing behavior, and water intake was analyzed with one-way repeated measures ANOVAs with drug dose as the independent variable; Tukey HSD post-hoc analyses were conducted to compare behaviors between vehicle and drug treatment days, as appropriate.
Results
Effects of 5-HT 3 receptor manipulations of the NAcc on intake and locomotion
In food-restricted animals offered rat chow, 5-HT 3 receptor stimulation of the NAcc yielded a significant effect of drug (N = 7; F 2,12 = 17.27, p < 0.001, p 2 = 0.74) and a significant drug X time interaction effect (F 46,276 = 7.09, p < 0.001, p 2 = 0.54). As can be seen in the top panels of Fig. 1 , 5-HT 3 receptor stimulation resulted in a dose-dependent increase in rat chow eaten over the 2-h feeding test. Follow-up ANOVAs at individual time points determined that food intake began to diverge by 20 min into the session. After 1 h of feeding, both doses of mCPBG had increased feeding as compared to the vehicle injection condition, and this effect continued throughout the remainder of the session for the 20.0 g/side condition. Despite this increase of food intake, 5-HT 3 receptor stimulation had no effect on ambulation ( Ondansetron did not affect ambulation, rearing, or water intake for food-restricted rats (all p's > 0.10); for rats offered the palatable diet, ondansetron increased rearing at 2.0 g/side (F 3,18 = 3.67, p = 0.041, p 2 = 0.36), but did not impact ambulation or water intake (both p's > 0.10).
Effects of 5-HT 3 receptor manipulations of the ventral tegmentum on intake and locomotion
In contrast to the increases in food intake seen following NAcc treatment, stimulation of 5-HT 3 receptors of the ventral tegmentum dose-dependently decreased food intake in foodrestricted rats offered rat chow (N = 9; drug effect: F 2,16 = 17.66, p < 0.001, p 2 = 0.69; drug X time interaction: F 46,368 = 5.60, p < 0.001, p 2 = 0.41). As can be seen in Fig. 2 , inhibition of feeding occurred within the first 5 min of the session and continued through the remainder of the 2 h test. Likewise, water intake was also reduced at both drug doses ( It is possible that this statistic was limited due to the low overall feeding on the palatable diet in this group (creating a possible floor effect). Nonetheless, there was a qualitative difference in the pattern of feeding inhibition between the group tested under restriction conditions as compared to the palatable feeding condition group. The restricted group's feeding was most heavily inhibited early in the session, whereas the palatable diet group's feeding was modestly inhibited in the second hour of the session. Other behavioral measures were unaffected; drug Fig. 1 . Effects of NAcc stimulation or blockade of the 5-HT3 receptor on feeding, water intake, and locomotion. In food-restricted rats offered rat chow, 5-HT3 receptor stimulation dose-dependently increased food intake; water intake and locomotor measures were not affected. A similar dose-dependent increase in food intake was also observed following mCPBG treatment in non-deprived rats offered a palatable diet. In this case, water intake was significantly reduced, though locomotor measures were unaffected. Antagonism of NAcc 5-HT3 receptors with ondansetron did not impact feeding or water intake in either paradigm, though 2.0 g/side increased rearing behavior in rats offered the palatable diet. Statistical symbols: *p < 0.05, **p < 0.01 for drug effects; single and double crosses demark p < 0.05 and p < 0.01 for drug X time interaction effect, respectively. Plus signs along the bottom of feeding graphs indicate times when there were significant simple effects of drug on food intake across drug doses. White stars treatment did not alter water consumption (F 2,12 = 0.34, p = 0.716, p 2 = 0.05), ambulation (F 2,12 = 0.16, p = 0.851, p 2 = 0.03) or rearing (F 2,12 = 0.14, p = 0.873, p 2 = 0.02) in rats offered the palatable diet.
Blockade of the ventral tegmental 5-HT 3 receptor had no significant effects on behavior. Food intake was not altered by VTA treatment in food-restricted rats (N = 6; drug effect: 
Discussion
The goal of these experiments was to determine if 5-HT 3 receptors of the mesoaccumbens pathway influence feeding in response to energy need, or as motivated by the presence of a palatable diet. To our knowledge, this is the first report to examine the role of mesoaccumbens 5-HT 3 receptors on food-directed motivation. Our findings demonstrate that 5-HT 3 receptor activation of the NAcc and ventral tegmentum affect feeding behavior in opposing manners. Specifically, stimulation of 5-HT 3 receptors in the anterior medial NAcc dose-dependently increased both hungerdriven and palatable feeding. In contrast, agonist treatments of 5-HT 3 receptors within the ventral tegmentum inhibited feeding in food-restricted rats offered rat chow, though intake was not significantly impacted in non-restricted animals presented with the palatable diet. Water intake was decreased by 5-HT 3 receptor stimulation in two groups: the VTA-treated group offered rat chow, and the NAcc-treated group given access to the palatable diet. In the former case, it is likely that the water intake decrease was linked to the reduced consumption of the dry rat chow. The decreased water consumption observed here after NAcc treatment has not been observed with other treatments that enhance feeding on the palatable diet, such as 5-HT 6 or mu-opioid receptor stimulation of the NAcc [13, 29] . Despite the behavioral changes observed with 5-HT 3 receptor stimulation, there were no effects of regional 5-HT 3 receptor blockade on feeding following ondansetron injection into either the ventral tegmentum or the NAcc.
Although these experiments suggest that 5-HT 3 receptors of the NAcc and VTA are involved in food intake, there is a possibility that the observed effects resulted from impacts of the drugs on nearby regions. It should be noted, however, that the volume and injection rate of the drug solutions used here has been successfully utilized by a number of laboratories to identify functional differences between the closely-positioned NAcc core and shell on learning and motivation [e.g. [34] [35] [36] ]. Additionally, Mena and colleagues [37] recently reported on the potential function of serotonergic agents of the medial prefrontal cortex in feeding. In their report, stimulation of serotonin receptors of the ventromedial prefrontal cortex (with serotonin hydrochloride) had no effect on feeding during a 60-min session. Assuming that those injections stimulated 5-HT 3 receptors (along with other 5-HT receptor subtypes), it seems unlikely that the effects we observed in the NAcc groups were due to diffusion of mCPBG to the nearby medial prefrontal cortex.
5-HT 3 receptor modulation of the mesoaccumbens circuit
The 5-HT 3 receptor is an ionotropic cation channel, and its activation rapidly depolarizes the membrane [24, 38] . Further experimental scrutiny will be required to determine which of the several cell populations within the tegmentum and ventral striatum possess the receptor, and how their activation may alter the functional output of the circuitry. Though 5-HT 3 receptors are known to modulate multiple neurotransmitter systems in cortical and hindbrain systems, including both glutamate and GABA signaling [e.g. [39] [40] [41] [42] ], the examination of their influence on signaling within the ventral tegmentum and NAcc has been primarily concentrated on dopamine output. 5-HT 3 receptor stimulation of either region increases dopamine outflow [22, 23] , and mCPBG injections into the posterior VTA support self-administration behavior [32] . Despite the similar effects of 5-HT 3 receptor stimulation on dopamine output in both regions, here we report that 5-HT 3 receptor stimulation increased food intake when applied to the NAcc and inhibited feeding in restricted rats offered rat chow when injected into the ventral tegmentum. One possible reason for this difference across brain regions is that the temporal character of the dopamine release likely differs following tegmental or NAcc 5-HT 3 agonism. For instance, NAcc dopamine release may be enhanced by 5-HT 3 receptor stimulation in a manner that is consistent with afferent signaling of natural reinforcement by midbrain dopamine neurons, whereas VTA injections may directly impact dopamine output by altering the firing properties of dopaminergic neurons in a reinforcement-independent manner. Thus, the latter may be more disruptive of natural reward/reinforcement mechanisms than the former.
Additional insight into the functional role of 5-HT 3 -dopamine interactions has been provided by researchers interested in the possible effects of 5-HT 3 receptor treatments on drug abuse. For instance, a robust literature has demonstrated that systemic alcohol increases dopamine output within the NAcc, and this increase can be reversed by blockade of 5-HT 3 receptors [e.g. [24, 25, 43, 44] ]. In a set of elegant studies, McBride and colleagues demonstrated that this may be mediated by 5-HT 3 receptors within the ventral tegmentum, as VTA injections of a 5-HT 3 antagonist reduces dopamine output within the NAcc in response to i.p. injections of ethanol [22] . Furthermore, 5-HT 3 antagonist treatments also block lever-pressing for posterior VTA infusions of alcohol or cocaine [45] . Indeed, preclinical studies have shown that under certain access conditions, 5-HT 3 receptor antagonism can reduce ethanol intake in rats [see [24] for review]. Similar reduced dopamine outflow in the NAcc following 5-HT 3 receptor antagonism has also been shown following injections of cocaine [25, 26] or morphine [25, 27] , although the preclinical efficacy of 5-HT 3 receptor antagonism is less compelling than it is for alcohol [24] . Regardless, such data suggest an important role for 5-HT 3 receptors for modulating dopamine release in the mesoaccumbens pathway.
Dopamine has a long history of being associated with motivated behavior. For instance, it regulates some aspects of incentive processes, the learning about natural reinforcers, and the allocation of effort expended to earn reinforcement [e.g. [10, [46] [47] [48] ]. Furthermore, its signaling is a critical element for the addictive nature of drugs of abuse [e.g. [49] ]. Thus, it is interesting that the potential effects of 5-HT 3 antagonists on the seeking and consumption of alcohol, which may be due in part to reductions of dopamine signaling, are not mirrored in this set of experiments or in other studies that have looked at the effects of 5-HT 3 receptor antagonism on feeding. Several laboratories have failed to report changes in normal food intake following systemic 5-HT 3 receptor antagonism in food-restricted rats [50] [51] [52] [53] . Similarly, mice treated with the 5-HT 3 antagonist tropistron showed no effects on food intake, even in a glucose-induced obesity model [54] . In a paradigm designed to within the graphs denote significant differences from the vehicle control injection, as assessed by Tukey's HSD. The histology figures to the right represent the injection sites for each experiment, as charted within Paxinos and Watson [33] . Black-filled circles represent agonist injection sites; gray-filled circles denote antagonist injection sites. Fig. 2 . Effects of ventral tegmentum stimulation or blockade of the 5-HT3 receptor on feeding, water intake, and locomotion. Stimulation of 5-HT3 receptors significantly inhibited food and water intake. This effect on feeding was seen within the first five minutes of food exposure for both doses of mCPBG, and continued through the remainder of the 2-h session. No significant effects of the drug was observed on ambulation or rearing. Though a trend for a decrease in feeding was observed in sated animals offered a palatable diet for the 20.0 g/side treatment of mCPBG, there was no significant effect of drug treatment on consumption measures or locomotion in the non-deprived rats. Antagonism of ventral tegmentum 5-HT3 receptors had no effect upon feeding or locomotion in either paradigm. Statistical symbols and histology as in Fig. 1 , with the exception that white stars were not placed in the top left figure to denote significant differences in feeding from the vehicle condition, as all time points were significantly different.
test the effects of drug treatment on reinforcement, 5-HT 3 receptor blockade of the ventral tegmentum was without effect on lever pressing for saccharin or water reinforcement, though the same treatments reduced alcohol seeking in an operant task [55] . Furthermore, systemic ondansetron treatment alone does not appear to impact lever pressing for a food-associated secondary reinforcer, though dopaminergic receptor blockade does [56] . That 5-HT 3 receptor blockade does not affect normal feeding is striking given that 5-HT 3 receptor antagonists are routinely used to ameliorate nausea, vomiting, and lack of appetite after chemotherapy treatment in human patients [16] , and they also reverse anorexia in rats presented with diets with amino acid imbalances [57] . Together with the present data, this suggests that 5-HT 3 receptor antagonism, which appears to reduce the rewarding properties of drugs of abuse under some conditions, may not impact reinforcement for natural rewards in non-addictive settings [but see [50, 53] ]. Although more work needs to be done to better understand when and how 5-HT 3 receptor antagonism may interact with peripheral and central mechanisms of nausea and food intake, reports that demonstrate that 5-HT 3 receptor antagonists reduce alcohol intake without affecting feeding is promising in terms of their potential for treating drug abuse without reducing motivation for natural reinforcers.
5-HT 3 receptor stimulation, food intake, and motivation
The current data suggest that stimulation of 5-HT 3 receptors may serve differential motivational functions across disparate brain regions. These findings may help clarify why prior studies that examined the impact of systemic 5-HT 3 receptor stimulation on feeding or diet choice have yielded inconsistent outcomes. For instance, treatment with the peripheral agonist 2-methyl-5-HT does not affect food intake in deprived rats [58] , suggesting a limited role for peripheral receptors in normal feeding. With drugs that penetrate brain, male and female Wistar rats maintained ad-libitum on a choice of diets (high-fat, high carbohydrate, and high-protein sources) reduced their carbohydrate ingestion following systemic 5-HT 3 stimulation, though only females reduced their total diet consumption across a 2 or 12 h test [59] . MazzolaPomietto and colleagues [52] reported a transient inhibition of feeding (within the first hour), followed by transient hyperphagia (between 1 and 4 h), after systemic mCPBG treatment (10 mg/kg) in food-restricted male Wistar rats, though chin-rubbing behavior may have interfered with food intake early in the session. Recently, a similar transient inhibition of acute feeding was observed following SR 57227 (a 5-HT 3 agonist) treatment in food restricted, but not fed, mice [60] . That 5-HT 3 receptor stimulation does not appear to consistently reduce feeding when given systemically may suggest differential involvement of 5-HT 3 receptors in food intake under different dietary and deprivation conditions across the hindbrain (see introduction), the ventral tegmentum, and the NAcc.
Both the ventral tegmentum and the striatum are important for regulating motivational and learning processes. In these experiments, we specifically targeted the anterior medial nucleus accumbens (as opposed to other striatal regions) for two prominent reasons: (1) this region of the NAcc connects directly and indirectly to hypothalamic regions responsible for regulating food intake, and (2) the anterior NAcc shell has been heavily implicated in both feeding and hedonic evaluation. Stimulation of mu-opioid receptors within this "hedonic hotspot" is known not only to increase food intake ("wanting"), but also enhance the hedonic responses that rats show to sapid sucrose solutions ("liking"), unlike other regions of striatum [61] . Little is known as to whether 5-HT receptors impact hedonic evaluation. This study suggests that mCPBG stimulation of 5-HT 3 receptors in the anterior medial NAcc enhances "wanting", but it cannot determine if "liking" is also increased by such treatment. Ventral tegmental drug treatments, although capable of altering food intake, have not yet been reported to increase hedonic evaluation [62] . Future studies, looking at affective facial reaction or licking microstructure to sapid solutions in response to local drug infusions, will be needed to determine if and how serotonin modulation within these circuits affects hedonic evaluation.
Concluding remarks
These experiments demonstrate for the first time that 5-HT 3 receptors of the NAcc and ventral tegmentum are important modulators of feeding behavior. Stimulation, but not blockade, of these receptors impacted feeding in a differential manner dependent upon the region targeted and the motivational state of the animal. These data add to a growing understanding of the roles of serotonin receptors of the mesoaccumbens pathway on food intake and motivation, and provide important basic insight to the functional impact of 5-HT 3 receptor agents. Given current interest in the development of 5-HT 3 -targeting compounds (particularly antagonists) for potential use in the treatment of addiction and mental disorders [24, [63] [64] [65] [66] , it remains of interest to understand how 5-HT 3 (and other serotonin) receptors modulate the motivational functions of the mesoaccumbens pathway in both normal and addictive-like conditions.
